DNLI: Denali Therapeutics Inc

DNLI新闻

• 21:32 Denali Therapeutics Inc. (DNLI) Presents at Jefferies Global Healthcare Conference 2026 Transcript
• 13:52 Should You Buy, Sell or Hold BIIB Stock After it Rises Almost 12% YTD?
• 11:54 Denali Therapeutics: 'Strong Buy' On AVLAYAH Approval And End Of 2026 FTD-GRN Data
• 12:11 Leqembi Isn’t Enough To Save Biogen Momentum (NASDAQ:BIIB)
• 20:34 Stocks Settle Higher on Iran Peace Hopes and Tech Strength
• 16:14 Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
• 15:20 Stocks Climb on US-Iran Peace Hopes and Strength in Chipmakers
• 14:13 Stocks Supported by US-Iran Peace Deal Optimism
• 16:36 DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects
• 04:13 Denali: The First Commercial Validation Of The Blood-Brain Barrier Platform
• 17:38 DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?
• 18:27 Denali Stock Falls as Partner Takeda Ends Collaboration Deal
• 12:00 Denali Solved A Major Challenge In Treating A Rare Genetic Disease. Now, Shares Are Flying.
• 23:15 Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome - Slideshow (NASDAQ:DNLI) 2026-03-27
• 18:25 Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up
• 12:30 FDA Clears Denali Therapeutics Drug As First Brain-Penetrating Biologic For Rare Disease - Denali Therapeutics (NASDAQ:DNLI)
• 10:55 Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome Transcript
• 18:08 Denali Jumps, Pulling Regenxbio Higher, On Early FDA Approval
• 00:22 Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Virtual CNS Forum Transcript
• 15:32 Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock?
• 12:28 Stifel sees rare disease stocks gaining after FDA official exit
• 20:55 Denali Therapeutics Inc. (DNLI) Presents at TD Cowen 46th Annual Health Care Conference Transcript